2.72
+0.05(+1.87%)
Currency In USD
| Previous Close | 2.67 |
| Open | 2.71 |
| Day High | 2.85 |
| Day Low | 2.64 |
| 52-Week High | 7.22 |
| 52-Week Low | 1.09 |
| Volume | 1.41M |
| Average Volume | 1.53M |
| Market Cap | 193.58M |
| PE | -1.71 |
| EPS | -1.59 |
| Moving Average 50 Days | 2.22 |
| Moving Average 200 Days | 2.52 |
| Change | 0.05 |
If you invested $1000 in C4 Therapeutics, Inc. (CCCC) since IPO date, it would be worth $106.71 as of September 08, 2025 at a share price of $2.72. Whereas If you bought $1000 worth of C4 Therapeutics, Inc. (CCCC) shares 3 years ago, it would be worth $245.27 as of September 08, 2025 at a share price of $2.72.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
GlobeNewswire Inc.
Sep 04, 2025 11:00 AM GMT
Development Candidate Targeting IRAK4 Now Progressing Toward Clinical DevelopmentWATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targ
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting
GlobeNewswire Inc.
Sep 03, 2025 11:00 AM GMT
C4T to Host Webcast on September 20, 2025 at 3 pm ETWATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation scie
C4 Therapeutics to Participate in Upcoming March Investor Conferences
GlobeNewswire Inc.
Feb 24, 2025 12:00 PM GMT
WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will partici